Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Litwin, Alain H.
• dc.contributor.author Drolet, Martine
• dc.contributor.author Nwankwo, Chizoba
• dc.contributor.author Torrens, Marta
• dc.contributor.author Kastelic, Andrej
• dc.contributor.author Walcher, Stephan
• dc.contributor.author Somaini, Lorenzo
• dc.contributor.author Mulvihill, Emily
• dc.contributor.author Ertl, Jochen
• dc.contributor.author Grebely, Jason
• dc.date.accessioned 2025-01-20T15:31:05Z
• dc.date.available 2025-01-20T15:31:05Z
• dc.date.issued 2019
• dc.description.abstract The aim of this analysis was to evaluate perceived barriers related to HCV testing, management and treatment among physicians practicing in clinics offering opioid agonist treatment (OAT). C-SCOPE was a study consisting of a self-administered survey among physicians practicing at clinics providing OAT in Australia, Canada, Europe and the United States between April and May 2017. A 5-point Likert scale (1 = not a barrier, 3 = moderate barrier, 5 = extreme barrier) was used to measure responses to perceived barriers for HCV testing, evaluation and treatment across the domains of the health system, clinic and patient. Among the 203 physicians enrolled (40% USA, 45% Europe, 14% Australia/Canada), 21% were addiction medicine specialists, 29% psychiatrists and 69% were metro/urban. OAT physicians in this study reported poor access to on-site venepuncture (35%), point-of-care HCV testing (16%), and noninvasive liver disease assessment (25%). Only 30% of OAT physicians reported personally treating HCV infection. Major perceived health system barriers to HCV management included the lack of funding for noninvasive liver disease testing, long wait times to see an HCV specialist, lack of funding for new HCV therapies, and reimbursement restrictions based on drug/alcohol use. Major perceived clinic barriers included the lack of peer support programmes and/or HCV case managers to facilitate linkage to care, the need to refer people off-site for noninvasive liver disease staging, the lack of support for on-site phlebotomy and the lack of on-site delivery of HCV therapy. This study highlights several important modifiable barriers to enhance HCV testing, evaluation and treatment among PWID attending OAT clinics.
• dc.format.mimetype application/pdf
• dc.identifier.citation Litwin AH, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study. J Viral Hepat. 2019 Sep;26(9):1094-104. DOI: 10.1111/jvh.13119
• dc.identifier.doi http://dx.doi.org/10.1111/jvh.13119
• dc.identifier.issn 1352-0504
• dc.identifier.uri http://hdl.handle.net/10230/69194
• dc.language.iso eng
• dc.publisher Wiley
• dc.relation.ispartof J Viral Hepat. 2019 Sep;26(9):1094-104
• dc.rights © 2019 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword DAA
• dc.subject.keyword OST
• dc.subject.keyword Barriers
• dc.subject.keyword Hepatitis C
• dc.subject.keyword Opioid substitution therapy
• dc.subject.keyword People who inject drugs
• dc.subject.keyword Treatment
• dc.title Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion